会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • COMPOSITIONS OF MICROBIOTA AND METHODS RELATED THERETO
    • 微生物组合物及其相关方法
    • WO2013130773A2
    • 2013-09-06
    • PCT/US2013/028271
    • 2013-02-28
    • ETHICON ENDO-SURGERY, INC.THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPTIALKAPLAN, Lee, M.LIOU, Alice, P.TURNBAUGH, Peter, J.HARRIS, Jason, L.
    • KAPLAN, Lee, M.LIOU, Alice, P.TURNBAUGH, Peter, J.HARRIS, Jason, L.
    • A61K35/74A61K45/06C12Q1/68
    • A61K35/74A61K9/0053A61K35/741A61K45/06A61K2035/11C12Q1/689Y02A50/451Y02A50/473A61K2300/00
    • Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia . Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by substantially increasing or decreasing a relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure. Also provided are methods of altering microbiota in a subject by administering a composition to the subject thereby altering a microbiota in the subject so that the microbiota mimics a microbiota found in a subject responsive to a gastric bypass or other gastrointestinal bariatric or metabolic procedure. Methods and compositions of altering a relative abundance of microbiota to alter metabolic function and of altering a relative abundance of short chain fatty acids to alter metabolic function are also provided.
    • 提供了通过改变受试者中的微生物群来治疗体重相关病症和代谢疾病的方法和组合物。 一个方面提供了通过向受试者施用包括来自门的基本上纯化的微生物群的组合物,例如细菌属,变形杆菌属,紧密菌属和Verrucomicrobia或诸如类杆菌属,Verrucomicrobial,梭菌和肠杆菌属或类属的序列,从而改变受试者中的微生物群的方法和组合物 如Alistipes,Clostridium,Escherichia和Akkermansia。 另一方面包括用于改变微生物群的药物组合物,其包括治疗有效量的基本上纯化的微生物群和药学上可接受的载体。 另一方面包括在需要这种治疗的受试者中通过基本上增加或减少受试者的胃肠道中的微生物群的相对丰度而无需外科手术或除外科手术之外,来治疗病症(例如肥胖症)的方法。 还提供了通过向受试者施用组合物从而改变受试者中的微生物群的方式来改变受试者中的微生物群的方法,使得微生物群模拟响应于胃旁路或其他胃肠减肥或代谢过程的受试者中发现的微生物群。 还提供了改变微生物群的相对丰度以改变代谢功能并改变短链脂肪酸的相对丰度以改变代谢功能的方法和组合物。